scholarly journals Studies on Analogues of L-Cysteine and L-Cystine

Blood ◽  
1956 ◽  
Vol 11 (1) ◽  
pp. 19-30 ◽  
Author(s):  
AUSTIN S. WEISBERGER ◽  
LEIF G. SUHRLAND
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Acute Leukemia ◽  
Oral Administration ◽  
Myeloid Leukemia ◽  
Leukocyte Count ◽  
Chemotherapeutic Agents ◽  
Rapid Decrease ◽  
Total Leukocyte Count ◽  
Spleen Size

Abstract Selenium cystine was administered orally to 2 patients with acute leukemia and to 2 patients with chronic myeloid leukemia. In all patients there was a rapid decrease in the total leukocyte count as well as a decrease in spleen size. This effect was observed in patients refractory to other chemotherapeutic agents as well as in the usually resistant types of leukemia. In patients with chronic myeloid leukemia the immature granulocytes disappeared much more rapidly than the mature granulocytes. The most striking and consistent effects were observed in acute leukemia. One patient who had become resistant to 6-mercaptopurine appeared to reacquire sensitivity to this compound after receiving selenium cystine. These effects of selenium cystine on leukocytes correlate with the ability of selenium cystine to decrease the influx of S35 L-cystine by leukemic leukocytes in vitro. Other potentially effective analogues of cystine (or cysteine) may therefore be selected by this technic. No changes were detected in any of the organs attributable to selenium cystine toxicity. The nausea and vomiting associated with the oral administration of selenium cystine was so severe that it was not possible to administer selenium cystine for a sufficient period of time to determine whether an appreciable remission can be obtained in leukemia. Further study is necessary to determine whether selenium cystine has any practical applicability in the chemotherapy of leukemia. Although the mechanism of action of selenium cystine is not known, these striking effects of an analogue of cystine on leukemia are further suggestive of the importance of cystine (cysteine) in the metabolism of leukocytes.

Enhanced Growth Suppression of Philadephia1 Leukemia Cells in Mice by Targeting Both BCR-ABL and VEGF through the Antisense Strategy.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5257-5257
Author(s):  
Zhong Chao Han ◽  
Xiu Li Cong ◽  
Bin Li ◽  
Ren Chi Yang
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Microvessel Density ◽  
Myeloid Leukemia ◽  
K562 Cells ◽  
Chemotherapeutic Agents ◽  
Leukemia Cells ◽  
Vegf Expression ◽  
Erythroleukemia Cell

Abstract The Philadephia chromosome (Ph1) translocation results in the formation of the BCR-ABL oncogene in over 95% patients with chronic myeloid leukemia (CML). VEGF levels are elevated both in the plasma of CML patients and in conditioned media taken from CML cells. Therefore, simultaneous targeting of BCR-ABL and VEGF might be a rational strategy for attempting treatment of Philadephia1 leukemia. To test this hypothesis, we used an antisense strategy to downregulate BCR-ABL and VEGF expression in K562 cells, a human erythroleukemia cell line. In vitro, combination of bcr/abl and VEGF antisense oligodeoxyribonucleotides (AS-ODNs) exerted a specific synergistic antiproliferative effect on K562 cells and prominently sensitized K562 cells to apoptosis-inducing stimuli. In vivo, nude mice injected with K562 cells were treated systemically with BCR-ABL or VEGF AS-ODNs or with both ODNs in combination. In comparison with the mice treated with individual agents, the mice treated with both ODNs showed a slower growth of leukemia tumors, a reduction of microvessel density and an increased apoptosis in the tumors. These results demonstrate that targeting both BCR-ABL and VEGF may represent an excellent strategy to overcome the resistance to chemotherapeutic agents and ultimately to augment the efficacy of chemotherapy in CML.

Use of New Chemotherapeutic Agents in Acute and Chronic Myeloid Leukemia

1968 ◽  
Vol 17 (1) ◽  
pp. 255-257
Author(s):  
N. Quattrin ◽  
E. Dini
Keyword(s):  
Stem Cells ◽  
Chronic Myeloid Leukemia ◽  
Acute Leukemia ◽  
Myeloid Leukemia ◽  
Chemotherapeutic Agents ◽  
Positive Results ◽  
New Chemotherapeutic Agents

Our experience in the Imuran treatment of acute leukemia is rather scarce. Indeed because of the difficulty to get this drug, we could use it in 6 cases only. These 6 cases belonged to the following forms: 3 to the stem cells type, 1 to the myelomonocytic type, 1 to the histiomonocytic ungranulated type, 1 to the promyelocytic type (acute terminal crisis of chronic myeloid leukemia). All these patients had been already treated with other antiblastics.Positive results we had just in 2 cases, precisely in a case of stem cells leukemia and in the last case above mentioned. Similar results in acute relapsing phase of chronic myeloid leukemia obtained Eridani et al. (1965). Where we applied strong doses (mg 30c of Imuran daily for 10 days), following the advice of Storti and Traldi (1965), and thus obtained a full three months remission (Fig. 1).According to this modest experience of ours Azathioprine is a drug that does not present clear advantages on 6-Mercaptopurin.

scholarly journals Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Lugyanti Sukrisman
Keyword(s):  
Acute Myeloid Leukemia ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukocyte Count ◽  
Endothelial Activation ◽  
Enzyme Linked Immunosorbent Assay ◽  
Newly Diagnosed ◽  
Prothrombin Fragment ◽  
Soluble P ◽  
Acute Myeloid

Abstract Background Myeloid cells express microparticles that could increase the expression of adhesion molecules including P-selectin. We aimed to evaluate the level of soluble P-selectin (sP-selectin) and prothrombin fragment 1 + 2 (F1 + 2), and to determine correlation of sP-selectin with leukocyte count and F1 + 2 levels in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Methods Patients with newly diagnosed AML (n = 25), CML (n = 13), and controls (n = 17) were recruited in this study. The diagnosis of AML and CML is based on 2001 WHO and/or FAB criteria. Levels of sP-selectin and F1 + 2 were determined using enzyme-linked immunosorbent assay kits (Behring ELISA Processor-III® and Behring Enzygnost F1 + 2). Results sP-selectin was significantly elevated in CML patients compared to AML patients (p = 0.001). Levels of F1 + 2 in AML and CML patients were significantly increased in comparison to controls (p < 0.001 and p = 0.043). Levels of sP-selectin were significantly correlated to leukocyte count (r = 0.437; p = 0.029) and F1 + 2 (r = 0.436; p = 0.029) in AML patients. Conclusions AML and CML patients had an increased tendency to thrombosis. While CML patients had higher platelet and/or endothelial activation, hypercoagulable state are more pronounced in AML patients.

siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo

2018 ◽  
Vol 130 ◽  
pp. 66-70 ◽  
Author(s):  
Juliana Valencia-Serna ◽  
Hamidreza M. Aliabadi ◽  
Adam Manfrin ◽  
Mahsa Mohseni ◽  
Xiaoyan Jiang ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Arrest Growth

Thymic Immunosuppressive Pentapeptide (TIPP) Showed Anticancer Activity in Breast Cancer and Chronic Myeloid Leukemia Both In Vitro and In Vivo

2021 ◽  
Vol 28 ◽  
Author(s):  
Muhammad Ijaz ◽  
Muhammad Shahbaz ◽  
Wenjie Jiang ◽  
Yikang Shi ◽  
Xiuli Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chronic Myeloid Leukemia ◽  
Anticancer Activity ◽  
Myeloid Leukemia ◽  
Map Kinases ◽  
Inflammatory Responses ◽  
Tumor Xenograft ◽  
Immunohistochemistry Analysis

Aim: Being the common cause and major burden of deaths globally, timely management of cancer is crucial. Background: Thymic immunosuppressive pentapeptide (TIPP) is a novel pentapeptide originally obtained from calf thymic immunosuppressive extract. Previously, TIPP has been proved to suppress the allergic and inflammatory responses in allergic mice via blocking MAP kinases/NF-κB signaling pathways. Objective: In this study, in vitro anticancer activity of TIPP was tested on two different types of cancers using MCF-7 and K562 cell lines. Methods: Tumor xenograft models for breast cancer and chronic myeloid leukemia were designed. In vivo anticancer activity of TIPP was investigated on both cancer types. The liver and tumor tissues of the mice were preserved for immunohistochemistry analysis. Results: In vitro anticancer activity of TIPP showed significant inhibition on cell viability of both breast cancer and chronic myeloid leukemia. In vivo anticancer effect of TIPP in both types of cancer models further proved the potent anticancer nature of TIPP. Immunohistochemistry analysis assured that TIPP is a safe drug for normal organs such as the liver. Conclusion: Our present study revealed that TIPP is a potent anticancer drug and an important treatment option for various diseases. Further work is needed to test the flexible and proficient activity of the novel peptide.

scholarly journals Detection of breakpoint cluster region- negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow

Blood ◽  
1990 ◽  
Vol 76 (11) ◽  
pp. 2404-2410 ◽  
Author(s):  
AG Turhan ◽  
RK Humphries ◽  
CJ Eaves ◽  
MJ Barnett ◽  
GL Phillips ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematopoietic Cells ◽  
Breakpoint Cluster Region ◽  
Cluster Region ◽  
Differentiated Cells ◽  
The One

Abstract Philadelphia (Ph1) chromosome-positive clonogenic progenitors usually disappear within 4 to 6 weeks in long-term cultures established from the marrow of patients with chronic myeloid leukemia (CML). In contrast, coexisting chromosomally normal hematopoietic cells are relatively well maintained. Thus, even though normal cells are initially undetectable, they may become the predominant population. Recently, we have begun to explore the potential of such cultures as a strategy for preparing CML marrow for autografting, and based on cytogenetic studies of the differential kinetics of Ph1-positive and Ph1-negative clonogenic cells, have chosen a 10-day period in culture to obtain maximal numbers of selectively enriched normal stem cells. Here we present the results of molecular analyses of the cells regenerated in vivo for the initial three CML patients to be treated using this approach by comparison with the differentiated cells generated by continued maintenance of an aliquot of the autograft in vitro (using a slightly modified culture feeding procedure to enhance the production and release of cells into the nonadherent fraction after 4 weeks) for the one patient whose genotype made molecular analysis of clonality status also possible. These analyses showed that cells with a rearranged breakpoint cluster region (BCR) gene were not detectable by Southern blotting in either in vitro or in vivo populations of mature cells that might be assumed to represent the progeny of primitive cells present at the end of the initial 10 days in culture. Production of BCR- negative cells was also shown to be temporally correlated with the appearance of nonclonal hematopoietic cells both in culture and in vivo. These findings provide support for the view that prolonged maintenance of CML marrow cells in long-term culture may allow molecular characterization of both the BCR-genotype and clonality status of cells with in vivo regenerative potential.

Sign in / Sign up

Export Citation Format

Share Document